Long-Term Debt: jaspertherapeutics.com (JSPR)

Brandmark of Jasper Therapeutics Inc (JSPR)

The price action visualization for Jasper Therapeutics (JSPR) demonstrates long-term debt, which currently stands at 0.00. Jasper Therapeutics specializes in cancer cell therapy, protecting its stem cell developments through patents and exclusive status. A team of leading geneticists and physicians is creating innovative transplantation methods while strictly adhering to government biosafety regulations and basic environmental standards.

JSPR (Jasper Therapeutics, Inc.) Company Long-Term Debt history from 07/04/2022 to 10/30/2026

Jasper Therapeutics, Inc. - analytical breakdowns and key metrics (JSPR)

- current quotes and average value forecast:
Stock Quotes Jasper Therapeutics Inc|JSPR - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Jasper Therapeutics|JSPR - Total Company Value
- book capitalization data:
Net Assets per Single Share Jasper Therapeutics|JSPR - Company Book Value|Market-to-Book Ratio jaspertherapeutics.com|JSPR - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio Jasper Therapeutics|JSPR - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Jasper Therapeutics Inc|JSPR - Company Total Debt|Debt to Net Assets Ratio Jasper Therapeutics|JSPR - Company Long-Term Debts|Company Current Liabilities Jasper Therapeutics|Immediate Liquidity jaspertherapeutics.com
- net income and valuation multiples indicators:
JSPR - Company Net Income
Fundamental company valuation:Jasper Therapeutics
Core merchandise of jaspertherapeutics.com

Investors must balance the growth potential of shares with the debt load, which determines the business's financial stability. The current level of long-term debt for Jasper Therapeutics (JSPR) reflects the dynamics of borrowed capital and default risk, which is critical for Jasper Therapeutics (JSPR) given the outsourcing of briquilimab production and fixed R&D costs, as the absence of proprietary plants minimizes the need for capital loans.

Who Jasper Therapeutics competes with

LEGN - Company Long-Term Liabilities|SANA - Company Long-Term Debt|Long-Term Debt Autolus Therapeutics PLC|Allogene Therapeutics Inc (ALLO) - Company Long-Term Debt|RNAC (Selecta Biosciences Inc.) - Company Long-Term Debt|Company Long-Term Debt Cellectis SA|Long-Term Debt cariboubio.com CRBU|Company Long-Term Debts TIL|genenta.com (GNTA) - Long-Term Indebtedness|Century Therapeutics, Inc. - Company Long-Term Liabilities|Senti Bio (SNTI) - Long-Term Debt|ADAP: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings CERO (CERo Therapeutics)|TCRT: Company Long-Term Debts|Company Long-Term Liabilities Achilles Therapeutics plc|CRGX (Cargo Therapeutics) - Company Long-Term Debts|Long-Term Debt Poseida Corp PSTX|Company Long-Term Debt 2seventy bio, Inc. (TSVT)|Company Long-Term Debt GRCL (gracellbio.com)